Around the world, pharmaceutical manufacturers and researchers’ objectives remain the same. To protect the safety of our community and to supply essential medicines for those who need them. This is our unique responsibility as an industry.
Sypharma is honoured to announce that we have collaborated with the University of Queensland’s Rapid Response Vaccine Pipeline Program, for the fill and finish of their SARS-CoV-2 Sclamp Vaccine for Phase 1 clinical trials that will be performed in Australia. This collaboration see Sypharma aseptically fill this drug substance into its final packaging format.
The Phase 1 Clinical Material is due to be in patients arms by July 2020.
Sypharma specialises in Aseptic Fill and Finish for contact projects with the majority of our clients within Phase 1 and Phase 2 Clinical Space.